Research Alliance III, a blank check company formed by RA Capital targeting drug development and healthtech, filed on Tuesday with the SEC to raise up to $50 million in an initial public offering.
The company plans to raise $50 million by offering 5 million shares at $10. Unlike most SPACs, the company is offering shares, instead of units with warrants and/or rights attached.
Research Alliance III is led by CEO and Director Matthew Hammond, a Partner on the Investment Team at RA Capital Management. The SPAC intends to target healthcare-related industries, specifically companies in the drug development and commercialization, diagnostic and healthcare technology and service sectors. The company may pursue a target affiliated with RA Capital.
RA Capital's previous SPACs include Research Alliance II (RACB), which went public in 2021 and liquidated; and Research Alliance I, which merged with POINT Biopharma (PNT; acquired by Eli Lilly) in 2021.
The New York, NY-based company was founded in 2026. It plans to list on the Nasdaq under the symbol RACC. Leerink Partners is the sole bookrunner on the deal.
RA Capital's SPAC Research Alliance III files for a $50 million IPO
March 24, 2026
